

Dec 26 2014 : The Times of India (Ahmedabad)

Torrent Pharma inks pact with Reliance Life to sell biosimilars

*Ahmedabad:
TNN*

Torrent Pharmaceuticals has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in India -Rituximab, Adalimumab and Cetuximab.

As per the agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for a period of 10 years. Rituximab and Cetuximab cater to the oncology segment and are used in the treatment of various cancers like leukemia, lymphoma, colorectal, head and neck cancers. Adalimumab is the most preferred therapy for the treatment of auto immune disorders like rheumatoid arthritis, psoriasis and IBD.

THE TIMES OF INDIA

Publication : The Times of India
Date : December 26, 2014
Page : 1 of 1
Title : Torrent Pharma inks pact with Reliance Life to sell biosimilars